BioSpace News Archive

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2019 financial results before the Nasdaq Global Market open on Tuesday, March 10, 2020. Jill C. Milne, Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and last year’s financial results.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration to bring its target enrichment and sample library preparation kits to a novel automation platform developed by Miroculus, Inc.

PhysIQ and the U.S. VA publish results of a clinical trial that demonstrates how artificial intelligence (AI) applied to continuous wearable sensor data may predict hospitalizations.

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced it will present new data from the clinical trial program for PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first-ever peanut allergy treatment approved by the U.S. Food and Drug Administration (FDA).

Company’s Flagship Product, Clinical Studio, to be Consolidated under TrialKit Brand

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, has received 510(k) clearance (k191832) for its novel push-button needle.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that the Company’s Board of Directors has approved a second-quarter 2020 dividend of $0.16 per share.

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended Dec. 31, 2019.

Recognition honors those companies that take the long view with a purpose-based strategy and strive to create positive change throughout their global communities

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will present at the Cowen and Company’s 40th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 11:20 a.m. ET.